Title : Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study.

Pub. Date : 2022 May

PMID : 35023208






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 WHAT IS KNOWN AND OBJECTIVE: Although osimertinib achieved convincing efficacy for patients with EGFR T790M-positive non-small-cell lung cancer (NSCLC) as second-line treatment in the AURA3 clinical trials, patients developed drug resistance ultimately. osimertinib epidermal growth factor receptor Homo sapiens